Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Docetaxel-associated epiphora.

Polly E Kintzel1, Laura B Michaud, Marianne K Lange

  • 1Department of Pharmacy, Spectrum Health Hospitals, Grand Rapids, Michigan 49503, and Division of Pharmacy, University of Texas M. D. Anderson Cancer Center, Houston, USA. polly.kintzel@spectrum-health.org

Pharmacotherapy
|May 24, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mirvetuximab soravtansine dosing weight considerations.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2025
Same author

Carboplatin desensitization - simplified 4-step 2-bag method.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2024
Same author

Loncastuximab tesirine: Risk for dose variance.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2024
Same author

Elotuzumab: Empiric analysis of dexamethasone administration schedule.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2023
Same author

International Society of Oncology Pharmacy Practitioners (ISOPP) position statement: Role of the oncology pharmacy team in cancer care.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2021
Same author

ONS Guidelines™ for Cancer Treatment-Related Hot Flashes in Women With Breast Cancer and Men With Prostate Cancer.

Oncology nursing forum·2020

Weekly docetaxel offers improved dose intensity for advanced cancers but can cause epiphora, or excess tearing. Patients and clinicians must recognize and manage this side effect to maintain quality of life during treatment.

Area of Science:

  • Oncology
  • Pharmacology
  • Ophthalmology

Background:

  • Docetaxel is a key chemotherapy agent for breast, prostate, and lung cancers.
  • Standard intermittent dosing (60-100 mg/m2 every 3 weeks) often leads to myelosuppression, with neutropenia as the dose-limiting toxicity.
  • Weekly docetaxel (20-42 mg/m2) is explored to enhance dose intensity and patient tolerance.

Purpose of the Study:

  • To investigate the adverse effects of weekly docetaxel administration.
  • To highlight epiphora (excess tearing) as a significant, potentially underreported side effect.
  • To emphasize the need for patient education and clinical monitoring of epiphora.

Main Methods:

  • Review of clinical observations and literature regarding weekly docetaxel administration.

Related Experiment Videos

  • Analysis of adverse events associated with docetaxel, focusing on ocular symptoms.
  • Assessment of the impact of epiphora on patient quality of life and treatment adherence.

    • Main Results:

    • Weekly docetaxel, while increasing dose intensity, is associated with asthenia, peripheral neuropathy, and epiphora.
    • Epiphora, caused by lacrimal outflow pathway issues, can significantly impair daily activities and quality of life.
    • This ocular side effect may be underrecognized due to patient reluctance and clinician oversight.

    Conclusions:

    • The expanding use of weekly docetaxel necessitates increased awareness of epiphora.
    • Educating patients to report tearing and eye irritation is crucial for early detection.
    • Clinicians must actively monitor for and manage treatment-related epiphora to ensure optimal patient care and treatment continuation.